- Home
- REVBW vs VCEL Comparison
REVBW vs VCEL Comparison
Compare REVBW & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVBW
- VCEL
- Stock Information
- Founded
- REVBW N/A
- VCEL 1989
- Country
- REVBW United States
- VCEL United States
- Employees
- REVBW 9
- VCEL N/A
- Industry
- REVBW Biotechnology: Pharmaceutical Preparations
- VCEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- REVBW Health Care
- VCEL Health Care
- Exchange
- REVBW Nasdaq
- VCEL Nasdaq
- Market Cap
- REVBW N/A
- VCEL N/A
- IPO Year
- REVBW 2020
- VCEL 1997
- Fundamental
- Price
- REVBW $0.02
- VCEL $58.52
- Analyst Decision
- REVBW
- VCEL Strong Buy
- Analyst Count
- REVBW 0
- VCEL 7
- Target Price
- REVBW N/A
- VCEL $63.29
- AVG Volume (30 Days)
- REVBW N/A
- VCEL 435.3K
- Earning Date
- REVBW N/A
- VCEL 02-27-2025
- Dividend Yield
- REVBW N/A
- VCEL N/A
- EPS Growth
- REVBW N/A
- VCEL N/A
- EPS
- REVBW N/A
- VCEL 0.07
- Revenue
- REVBW N/A
- VCEL $226,844,000.00
- Revenue This Year
- REVBW N/A
- VCEL $23.50
- Revenue Next Year
- REVBW N/A
- VCEL $21.74
- P/E Ratio
- REVBW N/A
- VCEL $800.56
- Revenue Growth
- REVBW N/A
- VCEL 22.48
- 52 Week Low
- REVBW N/A
- VCEL $39.12
- 52 Week High
- REVBW N/A
- VCEL $63.00
- Technical
- Relative Strength Index (RSI)
- REVBW N/A
- VCEL 54.56
- Support Level
- REVBW N/A
- VCEL $58.15
- Resistance Level
- REVBW N/A
- VCEL $63.00
- Average True Range (ATR)
- REVBW 0.00
- VCEL 2.38
- MACD
- REVBW 0.00
- VCEL 0.07
- Stochastic Oscillator
- REVBW 0.00
- VCEL 52.72
About REVBW Revelation Biosciences Inc. Warrant
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).